A combination of tetramethylpyrazine and berberine prevents coronary microembolization in rats by regulating miR-34a-5p in platelet-derived exosomes

Quick Facts

  • Publication title: A combination of tetramethylpyrazine and berberine prevents coronary microembolization in rats by regulating miR-34a-5p in platelet-derived exosomes
  • Journal: J Ethnopharmacol
  • Year: 2025
  • DOI: 10.1016/j.jep.2025.120549
  • PMID/PMCID: 40915375

Research overview

This study was designed to explore the potential role and mechanisms of TMP combined with BBR in reducing the formation of coronary microembolization (CME) in rats. Chuanxiong rhizome and Coptis chinensis are a classic herbal pair in Traditional Chinese Medicine (TCM), renowned for their effects in activating blood circulation and resolving toxicity.

Key findings

The combination of TMP and BBR significantly mitigated CME formation, myocardial injury, and left ventricular ejection fraction (LVEF) in rats.

Besides, the pretreatment with TMP and BBR inhibited platelet activation, alleviated endothelial cell damage, and reduced the number of M1 macrophages.

Additionally, the levels of miR-34a-5p in PLT-exo of CME rats were suppressed after the pretreatment with TMP and BBR.

However, these effects of TMP and BBR were attenuated after the injection of agomiR-34a-5p in CME rats.

Study design

CME was induced by the injection of sodium laurate into the left ventricular of rats.

CME formation and myocardial damage were examined using histopathology, while echocardiography was used to assess cardiac functions.

Moreover, TMP and BBR were added to observe their effects.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, qPCR validation.

Related platforms: Exoomics®

Related services and capabilities: Biofluid EV Isolation & Purification, qPCR Validation

References

Original publication: A combination of tetramethylpyrazine and berberine prevents coronary microembolization in rats by regulating miR-34a-5p in platelet-derived exosomes Journal of ethnopharmacology. 2025. DOI: 10.1016/j.jep.2025.120549. PMID/PMCID: 40915375.